Pharmaceutical delivery device having a siloxane polymer matrix

Claim 2

A pharmaceutical delivery device comprising (A) a biologically acceptable silicone polymer matrix, (B) an organopolysiloxane-polyoxyalkylene copolymer, which is effective as a dispersing agent in the production of a water-in-oil emulsion in which the continuous phase comprises a silicone component and (C) a drug component which is selected from polar and hydrophilic liquids comprising a pharmaceutically-active material, said liquid being dispersed throughout the matrix (A) in small compartments having on average a diameter below 20 microns.

Claim 3

A pharmaceutical delivery device according to claim 1 wherein the small compartments of (C) have on average a diameter below 10 microns.

Claim 4

A pharmaceutical delivery device according to claim 2 wherein the small compartments of (C) have on average a diameter below 5 microns.

Claim 5

A pharmaceutical delivery device according to Claim 1 wherein the organopolysiloxane-polyoxyalkylene copolymer (B) has the average formula Z(Me).sub.2 SiO[(Me).sub.2 SiO].sub.x [(Me)(R)SiO].sub.y [(Me)(AR')SiO].sub.z Si(Me).sub.2 Z wherein Me denotes a CH 3 R radical, A denotes a polyoxyalkylene radical having the formula --(OCH 2 CH 2 ) p (OCHCH 3 CH 2 ) q OR", R denotes an alkyl radical having from 6 to 16 carbon atoms, R' denotes an alkylene radical linking A to the silicon atom, R" is selected from the group consisting of a hydrogen atom and an alkyl radical having from 1 to 4 inclusive carbon atoms, Z is selected from the group consisting of a monovalent hydrocarbon radical having from 1 to 16 carbon atoms and a AR' radical, there being an average of at least one AR' radical and at least one R radical per molecule and the average values of x, y, z, p and q being such that p>q, p+q has a value sufficient to provide a radical weight for A of from 600 to 3500, x<3y, x+y+z has a value of from 30 to 400 and the total weight of A radicals in the organo- polysiloxane-polyoxyalkylene copolymer does not exceed a value of about 1/3 of the total weight of the organopolysiloxane.

Claim 6

A pharmaceutical delivery device according to claim 1 wherein the organopolysiloxane-polyoxyalkylene copolymer (B) contains at least one polydiorganosiloxane segment comprising siloxane units of the formula ##EQU3## wherein b has a value of from 0 to 3 inclusive, there being an average of approximately 2 R radicals per silicon atom in the copolymer and R is selected from the group consisting of methyl, ethyl, vinyl, phenyl and a divalent radical bonding a polyoxyalkylene segment to the polydiorganosiloxane segment, at least 95% of all R radicals being methyl and at least one polyoxyalkylene segment having an average molecular weight of at least 1000 and consisting of from 0 to 50 mol percent polyoxypropylene units and from 50 to 100 mol percent polyoxyalkylene units, at least one terminal portion of the polyoxyalkylene segment not bonded to the polydiorganosiloxane segment being satisfied by a terminating radical, the weight ratio of polydiorganosiloxane segment to polyoxyalkylene segments in the copolymer having a value of from 2/1 to 8/1.

Claim 7

A pharmaceutical delivery device according to claim 1 wherein the biologically acceptable silicone polymer matrix (A) results from the curing of a room temperature vulcanising organosilicone composition.

Claim 8

A pharmaceutical delivery device according to claim 1 wherein the biologically acceptable silicone polymer matrix (A) results from the curing of an elastomer-forming composition which comprises an organopolysiloxane having per molecule at least 2 silicon-bonded groups having olefinic unsaturation, an organosilicon compound having at least 2 silicon-bonded hydrogen atoms and a catalyst which promotes the reaction between olefinic groups and silicon-hydrogen groups.

Claim 9

A pharmaceutical delivery device according to claim 1 wherein the drug component (C) is selected from polar and hydrophilic liquid pharmaceutically active materials.

Claim 10

A pharmaceutical delivery device according to claim 1 wherein the drug component (C) is a pharmaceutically active material dispersed in one or more solvents selected from polar and hydrophilic solvents.

Claim 11

A pharmaceutical delivery device according to claim 1 wherein the drug component (C) is a pharmaceutically active material dissolved in one or more solvents selected from polar and hydrophilic solvents.

Claim 12

A pharmaceutical delivery device according to claim 9 wherein the solvent comprises polyethylene glycol having a molecular weight of from 200 to 2000.

Claim 13

A pharmaceutical delivery device according to claim 10 wherein the solvent comprises polyethylene glycol having a molecular weight of from 100 to 2000.

Claim 14

A pharmaceutical delivery device according to claim 1 wherein the device also comprises silicone polymers having a viscosity below 200 mm 2 /s.

Claim 15

A pharmaceutical delivery device according to claim 1 wherein the device also comprises a non-polar or hydrophobic pharmaceutically active material.

Claim 16

A process for making a pharmaceutical delivery device comprising stage (I) dispersing a drug component which is selected from polar and hydrophilic liquids comprising a pharmaceutically active material in an elastomer-forming organosilicone composition in the presence of an organopolysioxane-polyoxyalkylene copolymer, which is effective as a dispersing agent in the production of an emulsion comprising water dispersed in a silicone-containing continuous phase and stage (II) thereafter curing said elastomer-forming composition.

Claim 17

A process for making a pharmaceutical delivery device comprising stage (I) dispersing a drug component which is selected from polar and hydrophilic liquids comprising a pharmaceutically active material in an elastomer-forming organosilicone composition in the presence of an organopolysioxane-polyoxyalkylene copolymer, which is effective as a dispersing agent in the production of an emulsion comprising water dispersed in a silicone-containing continuous phase and stage (II) thereafter curing said elastomer-forming composition.

Claim 18

A process according to claim 15 wherein stage (I) comprises the steps of (1) preparing an emulsion by mixing together the organopolysiloxane-polyoxyalkylene copolymer, the polar or hydrophilic liquid medium comprising a pharmaceutically active material and an organosiloxane polymer, and (2) mixing the emulsion with an organosilicone composition which is elastomer-forming.

Claim 19

A process according to claim 15 wherein stage (I) comprises the steps of (1) preparing an emulsion by mixing together the organopolysiloxane-polyoxyalkylene copolymer, the polar or hydrophilic liquid medium comprising a pharmaceutically active material and an organosiloxane polymer, and (2) mixing the emulsion with an organosilicone composition which is elastomer-forming upon the incorporation of the organosiloxane polymer employed in step (1).